Xing Lin

427 total citations
24 papers, 300 citations indexed

About

Xing Lin is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Xing Lin has authored 24 papers receiving a total of 300 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Immunology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Xing Lin's work include Cancer-related molecular mechanisms research (4 papers), RNA modifications and cancer (4 papers) and interferon and immune responses (2 papers). Xing Lin is often cited by papers focused on Cancer-related molecular mechanisms research (4 papers), RNA modifications and cancer (4 papers) and interferon and immune responses (2 papers). Xing Lin collaborates with scholars based in China, Pakistan and Indonesia. Xing Lin's co-authors include Jie-wei Luo, Lihuan Zhu, Jianbin Huang, Jiguang Zhang, Jingjing Li, Jin Zhao, Chen Huang, Yiming Yang, Ki‐mook Kang and Xiaoqun Luo and has published in prestigious journals such as PLoS ONE, BioMed Research International and Cell Death and Disease.

In The Last Decade

Xing Lin

22 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xing Lin China 11 143 66 66 60 38 24 300
Haibin Sun China 12 183 1.3× 79 1.2× 36 0.5× 38 0.6× 18 0.5× 25 376
Ping Gao China 11 115 0.8× 34 0.5× 44 0.7× 44 0.7× 17 0.4× 22 293
Hanxi Wan China 9 166 1.2× 57 0.9× 74 1.1× 139 2.3× 15 0.4× 13 409
Hayley Duckles United Kingdom 5 153 1.1× 76 1.2× 47 0.7× 38 0.6× 32 0.8× 5 309
Amalia de Luca United Kingdom 4 124 0.9× 83 1.3× 42 0.6× 48 0.8× 31 0.8× 6 299
Kai Betteridge United Kingdom 7 165 1.2× 40 0.6× 36 0.5× 28 0.5× 48 1.3× 7 333
Gregory S. Harmon United States 7 229 1.6× 55 0.8× 40 0.6× 54 0.9× 39 1.0× 10 413
Ku-Geng Huo Canada 8 169 1.2× 67 1.0× 71 1.1× 54 0.9× 20 0.5× 13 425

Countries citing papers authored by Xing Lin

Since Specialization
Citations

This map shows the geographic impact of Xing Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xing Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xing Lin more than expected).

Fields of papers citing papers by Xing Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xing Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xing Lin. The network helps show where Xing Lin may publish in the future.

Co-authorship network of co-authors of Xing Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Xing Lin. A scholar is included among the top collaborators of Xing Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xing Lin. Xing Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Xing, et al.. (2025). Progress of ERK Pathway-Modulated Natural Products for Anti-Non-Small-Cell Lung Cancer Activity. Pharmaceuticals. 18(9). 1371–1371.
2.
He, Xinlong, Wenwen Zhang, Jie Liu, et al.. (2025). The global regulatory role of RsbUVW in virulence and biofilm formation in MRSA. Microbial Pathogenesis. 203. 107508–107508.
3.
Zhu, Lihuan, et al.. (2023). TRIM9 Interacts with ZEB1 to Suppress Esophageal Cancer by Promoting ZEB1 Protein Degradation via the UPP Pathway. BioMed Research International. 2023(1). 2942402–2942402. 6 indexed citations
4.
5.
Zhang, Jiguang, et al.. (2022). Indocyanine green fluorescence imaging improves the assessment of blood supply of interposition jejunum. Surgical Endoscopy. 36(9). 6456–6463. 2 indexed citations
6.
Lei, Yujie, et al.. (2022). Mxi1 participates in the progression of lung cancer via the microRNA-300/KLF9/GADD34 Axis. Cell Death and Disease. 13(5). 425–425. 11 indexed citations
7.
Zhang, Jiguang, et al.. (2022). UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT. Oncology Reports. 48(2). 11 indexed citations
8.
Wang, Xin, et al.. (2021). MiR-133a-3p inhibits the malignant progression of oesophageal cancer by targeting CDCA8. The Journal of Biochemistry. 170(6). 689–698. 13 indexed citations
9.
10.
Zhang, Jiguang, et al.. (2020). Three-dimensional printing technology for localised thoracoscopic segmental resection for lung cancer: a quasi-randomised clinical trial. World Journal of Surgical Oncology. 18(1). 223–223. 30 indexed citations
11.
Lin, Xing, et al.. (2020). TRIM2 directly deubiquitinates and stabilizes Snail1 protein, mediating proliferation and metastasis of lung adenocarcinoma. Cancer Cell International. 20(1). 228–228. 26 indexed citations
12.
Huang, Junpeng, et al.. (2020). A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer.. International Journal of Clinical and Experimental Pathology. 13(12). 3060–3082. 4 indexed citations
13.
Li, Jingjing, et al.. (2019). Astragaloside-IV protects H9C2(2-1) cardiomyocytes from high glucose-induced injury via miR-34a-mediated autophagy pathway. Artificial Cells Nanomedicine and Biotechnology. 47(1). 4172–4181. 62 indexed citations
14.
Li, Xiao‐Ming, Zhizhong Chen, Yan Chen, et al.. (2018). Diurnal rhythm of follicle-stimulating hormone is associated with nonalcoholic fatty liver disease in a Chinese elderly population. European Journal of Obstetrics & Gynecology and Reproductive Biology. 222. 166–170. 8 indexed citations
15.
16.
Lin, Xing, et al.. (2017). Management of Pleural Space After Lung Resection by Cryoneuroablation of Phrenic Nerve: A Randomized Study. Surgical Innovation. 24(3). 240–244. 7 indexed citations
17.
Lin, Xing, et al.. (2016). CYLD Promotes TNF-α-Induced Cell Necrosis Mediated by RIP-1 in Human Lung Cancer Cells. Mediators of Inflammation. 2016. 1–11. 18 indexed citations
18.
Yang, Yiming, et al.. (2009). An approach to the correlation between vitiligo and autoimmune thyroiditis in Chinese children. Clinical and Experimental Dermatology. 35(7). 706–710. 30 indexed citations
19.
Miller, Konstantin, et al.. (1996). Proliferation kinetics of chorionic villi in chromosomally normal and abnormal spontaneous abortions analyzed by premature chromosome condensation and northern blot.. PubMed. 39(3). 159–67. 2 indexed citations
20.
Yan, Xue, et al.. (1990). Treatment of functional headache with Chinese herbal inhalant--a report of 496 cases.. PubMed. 10(2). 94–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Haibin Sun Breakdown of academic impact, for papers by Ping Gao Breakdown of academic impact, for papers by Hanxi Wan Breakdown of academic impact, for papers by Hayley Duckles Breakdown of academic impact, for papers by Amalia de Luca Breakdown of academic impact, for papers by Kai Betteridge Breakdown of academic impact, for papers by Gregory S. Harmon Breakdown of academic impact, for papers by Ku-Geng Huo
Rankless by CCL
2026